Cargando…

Management of Autoimmune Status Epilepticus

Status epilepticus is a neurological emergency with increased morbidity and mortality. Urgent diagnosis and treatment are crucial to prevent irreversible brain damage. In this mini review, we will discuss the recent advances in the diagnosis and treatment of autoimmune status epilepticus (ASE), a ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirmani, Batool F., Barr, Donald, Robinson, Diana Mungall, Pranske, Zachary, Fonkem, Ekokobe, Benge, Jared, Huang, Jason H., Ling, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954092/
https://www.ncbi.nlm.nih.gov/pubmed/29867707
http://dx.doi.org/10.3389/fneur.2018.00259
_version_ 1783323453161472000
author Kirmani, Batool F.
Barr, Donald
Robinson, Diana Mungall
Pranske, Zachary
Fonkem, Ekokobe
Benge, Jared
Huang, Jason H.
Ling, Geoffrey
author_facet Kirmani, Batool F.
Barr, Donald
Robinson, Diana Mungall
Pranske, Zachary
Fonkem, Ekokobe
Benge, Jared
Huang, Jason H.
Ling, Geoffrey
author_sort Kirmani, Batool F.
collection PubMed
description Status epilepticus is a neurological emergency with increased morbidity and mortality. Urgent diagnosis and treatment are crucial to prevent irreversible brain damage. In this mini review, we will discuss the recent advances in the diagnosis and treatment of autoimmune status epilepticus (ASE), a rare form of the disorder encountered in the intensive care unit. ASE can be refractory to anticonvulsant therapy and the symptoms include subacute onset of short-term memory loss with rapidly progressive encephalopathy, psychiatric symptoms with unexplained new-onset seizures, imaging findings, CSF pleocytosis, and availability of antibody testing makes an earlier diagnosis of ASE possible. Neuroimmunomodulatory therapies are the mainstay in the treatment of ASE. The goal is to maximize the effectiveness of anticonvulsant agents and find an optimal combination of therapies while undergoing immunomodulatory therapy to reduce morbidity and mortality.
format Online
Article
Text
id pubmed-5954092
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59540922018-06-04 Management of Autoimmune Status Epilepticus Kirmani, Batool F. Barr, Donald Robinson, Diana Mungall Pranske, Zachary Fonkem, Ekokobe Benge, Jared Huang, Jason H. Ling, Geoffrey Front Neurol Neuroscience Status epilepticus is a neurological emergency with increased morbidity and mortality. Urgent diagnosis and treatment are crucial to prevent irreversible brain damage. In this mini review, we will discuss the recent advances in the diagnosis and treatment of autoimmune status epilepticus (ASE), a rare form of the disorder encountered in the intensive care unit. ASE can be refractory to anticonvulsant therapy and the symptoms include subacute onset of short-term memory loss with rapidly progressive encephalopathy, psychiatric symptoms with unexplained new-onset seizures, imaging findings, CSF pleocytosis, and availability of antibody testing makes an earlier diagnosis of ASE possible. Neuroimmunomodulatory therapies are the mainstay in the treatment of ASE. The goal is to maximize the effectiveness of anticonvulsant agents and find an optimal combination of therapies while undergoing immunomodulatory therapy to reduce morbidity and mortality. Frontiers Media S.A. 2018-05-09 /pmc/articles/PMC5954092/ /pubmed/29867707 http://dx.doi.org/10.3389/fneur.2018.00259 Text en Copyright © 2018 Kirmani, Barr, Robinson, Pranske, Fonkem, Benge, Huang and Ling. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Kirmani, Batool F.
Barr, Donald
Robinson, Diana Mungall
Pranske, Zachary
Fonkem, Ekokobe
Benge, Jared
Huang, Jason H.
Ling, Geoffrey
Management of Autoimmune Status Epilepticus
title Management of Autoimmune Status Epilepticus
title_full Management of Autoimmune Status Epilepticus
title_fullStr Management of Autoimmune Status Epilepticus
title_full_unstemmed Management of Autoimmune Status Epilepticus
title_short Management of Autoimmune Status Epilepticus
title_sort management of autoimmune status epilepticus
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954092/
https://www.ncbi.nlm.nih.gov/pubmed/29867707
http://dx.doi.org/10.3389/fneur.2018.00259
work_keys_str_mv AT kirmanibatoolf managementofautoimmunestatusepilepticus
AT barrdonald managementofautoimmunestatusepilepticus
AT robinsondianamungall managementofautoimmunestatusepilepticus
AT pranskezachary managementofautoimmunestatusepilepticus
AT fonkemekokobe managementofautoimmunestatusepilepticus
AT bengejared managementofautoimmunestatusepilepticus
AT huangjasonh managementofautoimmunestatusepilepticus
AT linggeoffrey managementofautoimmunestatusepilepticus